MDNA19 / Medicenna - LARVOL DELTA

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting (GlobeNewswire) - "Medicenna Therapeutics...announced new preclinical data highlighting the potent anti-tumor efficacy of the next-generation BiSKIT (Bi-functional SuperKines for ImmunoTherapy), anti-PD1-MDNA109FEAA, in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting....Treatment with the anti-PD1-IL-2 BiSKIT led to dose-dependent and statistically significant improvements in tumor growth inhibition and survival compared to co-administration of individual components, namely MDNA19 (MDNA109FEAA-Fc) and anti-PD1 in murine tumor models."

Preclinical • Oncology

Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting (GlobeNewswire) - “Key data and conclusions from the AACR poster include: MDNA19-MDNA413 showed enhanced signaling in cancer killing effector T cells and NK cells and reduced activation of pro-tumor Treg cells corresponding to a 209-fold and 90-fold enhancement in CD8/Treg and NK/Treg ratios, respectively, when compared to native IL-2. MDNA19-MDNA413 selectively binds and inhibits both, IL-4 and IL-13 signaling, via the alpha 1 subunit (IL13Rα1) of the Type II IL-4 receptor, which is normally associated with pro-tumoral effects due to stimulation of Myeloid Derived Suppressor Cells (MDSCs) and M2a polarization of Tumor Associated Macrophages (TAMs), while showing reduced affinity for the IL13Rα2 decoy receptor…MDNA19-MDNA413 potently inhibited both IL-4 and IL-13 mediated pSTAT6 activity with an IC50 of 8.0 and 12.3 nM, respectively.”

Preclinical • Oncology

Medicenna announces March 31, 2020 year-end results (PRNewswire) - "Upcoming Milestones: Meeting with the US FDA to discuss the development path forward for MDNA55. It is currently anticipated this meeting will be held in Q3 calendar 2020. Initiation of IND enabling studies for MDNA109 Superkine Platform (MDNA19 or MDNA11) in Q4 of calendar 2020. Initiation of Phase 1 clinical study for MDNA109 Superkine Platform (MDNA19 or MDNA11) in mid-2021."

FDA event • New P1 trial • New trial • Glioblastoma • Oncology

Medicenna's IL-2 superkine, MDNA19, demonstrates best-in-class features in a non-human primate study (PRNewswire) - “Medicenna Therapeutics Corp…will present pre-clinical data including non-human primate (NHP) data from its IL-2 Superkine program during a conference call and webcast today. The presentation (details below) will highlight data from the long-acting variant MDNA19, engineered to have enhanced binding to CD122 without binding to CD25. This allows MDNA19 to specifically activate naïve CD8 T cells and natural killer (NK) cells with minimal stimulation of T regulatory cells (Tregs), thereby circumventing toxicity and demonstrating potential for best-in-class features.”

Preclinical

Medicenna reports third quarter fiscal 2020 financial results (PRNewswire) - "'We have achieved a number of exciting and important milestones this quarter, both in the ongoing development of MDNA55 and MDNA19 and in further strengthening our financial position as we swiftly advance towards the important End of Phase 2 meeting with the FDA this spring'"

Clinical • FDA event